bms-790052 and Body-Weight

bms-790052 has been researched along with Body-Weight* in 1 studies

Other Studies

1 other study(ies) available for bms-790052 and Body-Weight

Article	Year
Effects of Dual Sofosbuvir/Daclatasvir Therapy on Weight and Linear Growth in Adolescent Patients with Chronic Hepatitis C Virus Infection. The Pediatric infectious disease journal, 2019, Volume: 38, Issue:7 Negative effects on growth indices had been reported in children treated with interferon for chronic viral hepatitis. Forty chronic hepatitis C virus-infected adolescents, 12-17 years of age, were treated with sofosbuvir/daclatasvir therapy for 12 weeks. The intent-to-treat sustained virologic response rate at 12 weeks after end of treatment was 39/40 (97.5%). Unlike interferon-based therapy, we did not detect significant negative effects on linear growth or weight. Contrarily, a trend to increased appetite and insignificant weight gain was observed, but further larger studies are needed to confirm. See Video-Abstract, http://links.lww.com/ASAIO/A381. Topics: Adolescent; Antiviral Agents; Body Height; Body Weight; Carbamates; Child; Child Development; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Pyrrolidines; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine	2019

Article

Year

Effects of Dual Sofosbuvir/Daclatasvir Therapy on Weight and Linear Growth in Adolescent Patients with Chronic Hepatitis C Virus Infection.

The Pediatric infectious disease journal, 2019, Volume: 38, Issue:7

Negative effects on growth indices had been reported in children treated with interferon for chronic viral hepatitis. Forty chronic hepatitis C virus-infected adolescents, 12-17 years of age, were treated with sofosbuvir/daclatasvir therapy for 12 weeks. The intent-to-treat sustained virologic response rate at 12 weeks after end of treatment was 39/40 (97.5%). Unlike interferon-based therapy, we did not detect significant negative effects on linear growth or weight. Contrarily, a trend to increased appetite and insignificant weight gain was observed, but further larger studies are needed to confirm. See Video-Abstract, http://links.lww.com/ASAIO/A381.

Topics: Adolescent; Antiviral Agents; Body Height; Body Weight; Carbamates; Child; Child Development; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Pyrrolidines; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2019